FDA lifts hold from Aastrom's Phase II study of cardiac repair cells
This article was originally published in Scrip
The US FDA has lifted its clinical hold on Aastrom's Phase II IMPACT-DCM trial evaluating cardiac repair cells (CRCs) for the treatment of dilated cardiomyopathy (DCM), which was imposed after a patient died in May (scripnews.com, May 28th, 2009).
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.